REGN Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for REGN from our risk checks.
Narratives
BetaNarratives bring a range of perspectives from our community.
Warren
Based on Analyst Price Targets
Price at publication US$972.10
Updated
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$993.29 |
52 Week High | US$1,001.04 |
52 Week Low | US$684.81 |
Beta | 0.17 |
1 Month Change | 3.79% |
3 Month Change | 2.18% |
1 Year Change | 32.77% |
3 Year Change | 96.14% |
5 Year Change | 223.72% |
Change since IPO | 4,601.96% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
May 21Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
May 06Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing
Apr 30Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
Apr 10Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Mar 26Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10Regeneron's Push Into Obesity, Q4 2023 Earnings Review
Feb 02These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
Jan 31Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
Oct 25Shareholder Returns
REGN | US Biotechs | US Market | |
---|---|---|---|
7D | 2.1% | 2.4% | -0.6% |
1Y | 32.8% | 6.7% | 21.7% |
Return vs Industry: REGN exceeded the US Biotechs industry which returned 6.7% over the past year.
Return vs Market: REGN exceeded the US Market which returned 21.7% over the past year.
Price Volatility
REGN volatility | |
---|---|
REGN Average Weekly Movement | 2.2% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.6% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: REGN has not had significant price volatility in the past 3 months.
Volatility Over Time: REGN's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1988 | 13,677 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
REGN fundamental statistics | |
---|---|
Market cap | US$106.75b |
Earnings (TTM) | US$3.86b |
Revenue (TTM) | US$13.10b |
27.8x
P/E Ratio8.2x
P/S RatioIs REGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
REGN income statement (TTM) | |
---|---|
Revenue | US$13.10b |
Cost of Revenue | US$6.38b |
Gross Profit | US$6.72b |
Other Expenses | US$2.86b |
Earnings | US$3.86b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 35.76 |
Gross Margin | 51.31% |
Net Profit Margin | 29.45% |
Debt/Equity Ratio | 7.3% |
How did REGN perform over the long term?
See historical performance and comparison